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Abstract 246 words. 
Metabolomic studies of body fluids show that immune-mediated inflammatory diseases such as 
rheumatoid arthritis (RA) are associated with metabolic disruption. This is likely to reflect the 
increased bioenergetic and biosynthetic demands of sustained inflammation and changes to nutrient 
and oxygen availability in damaged tissue. The synovial membrane lining layer is the principle site of 
inflammation in RA. Here the resident cells are the fibroblast-like synoviocytes (FLS) and the 
synovial tissue macrophages (STM), which are transformed toward overproduction of enzymes which 
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degrade cartilage and bone, and cytokines which promote immune cell infiltration. Recent studies 
have shown metabolic changes in both FLS and macrophages from RA patients and these may be 
therapeutically targetable. However, as the origins and subset specific functions of synoviocytes are 
poorly understood and the signaling modules which control metabolic deviation in RA synovial cells 
are yet to be explored, significant additional research is needed to translate these findings toward 
clinical application. Furthermore, in many inflamed tissues, different cell types can forge metabolic 
collaborations through solute carriers (SLC) in their membranes, to meet a high demand for energy or 
biomolecules. Such relationships are likely to exist in the synovium and are yet to be explored. 
Finally, it is not yet known whether metabolic change is a consequence of disease or if primary 
changes to cellular metabolism might underlie or contribute to early stage disease pathogenesis. This 
article collates what is known about metabolism in synovial tissue cells and highlights future research 
directions in this area. 
 
Introduction 
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease which principally manifests in 
the articular joints. Recent research has yielded biological therapies and small molecules to target 
signaling pathways and pathogenic components involved in inflammation and immunity, but in spite 
of these reasonably successful treatments, very few RA patients are able to achieve and stay in a state 
of drug-free remission. Innovative strategies are needed to obtain new insights into mechanisms 
which underlie disease pathogenesis and to identify potential new treatments.  
In fields such as oncology, the concept of undermining or reprogramming metabolism to improve 
patient outcomes is established and we and others believe the potential is great to adopt similar 
strategies in immune-mediated inflammatory diseases (IMID) (1, 2). For three decades researchers 
have hypothesized an intermediate role for metabolic alterations and local hypoxia in RA pathology 
(3, 4). Indeed, RA and related IMID are associated with systemically measurable metabolic 
disruption. This is likely to reflect the increased bioenergetic and biosynthetic demand placed on 
immune and stromal cells in a chronically activated state. We now have the tools to better understand 
and translate past observations and to explore our hypothesis that metabolic deviation in synovial cells 
has a role in early pathogenesis rather than being a consequence of tissue damage. Qualitative changes 
to cellular metabolism are indeed essential to support physiological and pathological responses seen in 
the RA synovium and we describe these changes below. RA-associated characteristics include 
proliferation, migration and invasion that are hallmarks of activated fibroblast-like synoviocyte (FLS) 
behavior, and also proinflammatory mediator production characteristic of activated synovial tissue 
macrophages (STM) (5-7). The phenotypic transformation of FLS from a quiescent cell to an 
aggressive, metabolically active cell, the activation of STM, and the increasingly hypoxic and nutrient 
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deprived microenvironment which develops in the RA joint are characteristics which closely resemble 
those seen in solid tumors.  
Immunometabolism research has recently expanded in the footsteps of the more advanced cancer 
metabolism literature and this has led to the identification of potential new drug targets for immune-
mediated pathologies(1, 8). Limitation of metabolic substrate availability, modulation of signaling 
pathways which control metabolism and targeting of channels through which metabolic intermediates 
are shared are exciting new strategies for treatment. Since there is now a widespread acceptance that 
the future of RA treatment may lie in targeting the synovial tissue and in particular the stromal 
microenvironment, it is logical to apply these new therapies here (9, 10). In this review, we describe 
our current knowledge of synovial metabolism and the therapeutic opportunities this field might 
present. We focus upon the FLS and STM which together form a destructive frontier and whose 
aberrant behavior is underpinned by pathological metabolic changes. 
 
A systemic metabolic phenotype in RA 
Metabolic perturbations have long been associated with RA and the hallmark ‘calor’ (heat) observed 
in the rheumatoid joint is widely considered a consequence of metabolic activity. Daily resting whole 
body energy expenditure is 8% higher in RA than in healthy individuals suggesting these metabolic 
changes are significant and systemic (11). RA patients have an increased susceptibility to 
cardiovascular comorbidity and metabolic syndrome during the progression of their disease, 
associated with disruption of lipid and glucose metabolism (12). Furthermore, the catabolic condition 
‘cachexia’ occurs in RA, with muscle atrophy and gain in fat associated with systemically elevated 
pro-inflammatory cytokines such as TNFα, IL-1β, LIF, IFNγ and IL-6 (13). Untargeted metabolomic 
studies of body fluids are helping to characterize the systemic observations alluded to above. These 
involve analysis of small molecules (<3kDa) usually using one-dimensional nuclear magnetic 
resonance (1D NMR) spectroscopy or mass spectrometry coupled to gas or liquid phase separation 
techniques, technologies which we have recently compared and evaluated (14). This approach has 
highlighted urinary metabolite signatures which can identify the six most prevalent immune-mediated 
inflammatory diseases (15), and a serum metabolite signature which correlates with C-reactive protein 
(CRP) level and associates metabolism with underlying inflammatory mechanisms (16). Serum (17) 
and synovial fluid (SF) (18, 19) metabolomic profiles have also demonstrated the potential to 
distinguish RA from psoriatic arthritis and other diseases (14). Furthermore, our data and that of 
others show that patient responses to biological therapies including etanercept and rituximab can be 
predicted from urine, serum and plasma metabolic profiles, highlighting the power of metabolomics in 
stratifying patients and directing RA treatment (20-22).  
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Since immune and stromal cells within the inflamed joints are known to produce inflammatory 
cytokines it is likely that they are contributing to the global metabolic phenotype in RA. However, the 
metabolic profiles of individual cell types involved in chronicity or resolution of inflammation have 
sparsely been elucidated. This will be important to link diseases associated metabolites to pathogenic 
processes and to gain a full understanding of RA pathogenesis. 
 
The rheumatoid synovium 
Though RA is a systemic disease, the major manifestation is joint pain and loss of function. The 
normal diarthrodial joint is lined with a thin, soft-tissue membrane, the synovium, which comprises a 
sublining and a thin intimal lining layer, and which produces and encapsulates a lubricating 
hyaluronic acid-rich fluid (23). Resident to the tissue are two heterogeneous and inadequately 
characterized cell types a) the STM; a mixed population of prenatally seeded cells and those which 
have differentiated from circulating monocytes (24, 25), and b) the FLS, mesenchymal-derived cells, 
which compared with fibroblasts in other anatomical locations, are characterized by the expression of 
UDP-glucose 6-dehydrogenase, an enzyme required for the synthesis of hyaluronic acid, and of 
complement decay-accelerating factor (also known as CD55) (26). Collaborative networks such as the 
National Institutes for Health Accelerating Medicines Partnership are facilitating the effective 
digestion of tissue to obtain pure populations of FLS and STM. This combined with a growing profile 
of soluble and surface markers and revolutions in fate mapping and single cell analysis techniques is 
improving our ability to study and understand the functions of these important cells (27, 28).  
The hallmark of RA is macroscopically visible change to the synovial lining layer which becomes 
inflamed, hyperplastic and invasive of local cartilage and bone (29). This is driven by a complex 
interaction between chronically activated and epigenetically transformed synoviocytes and infiltrating 
cells of the innate and adaptive immune system (5, 30). Both FLS and STM contribute to synovial 
inflammation by production of mediators which recruit and activate immune cells. Importantly, these 
cells also drive each other’s activation and survival by paracrine production of cytokines such as 
TNFα and GM-CSF (30). However, it is the FLS in the intimal lining which form the aggressive 
pannus and are the major effectors of tissue damage through production of extracellular matrix 
degrading enzymes such as matrix metalloproteinases and cathepsins (30).  
Though the joint exists at an oxygen tension as low as 8% even in health, the microenvironment in 
RA is characterized by severe hypoxia at oxygen tensions which fall to below 1% (31). Nutrient 
availability is also low as immune cells and activated synoviocytes consume available resources at a 
rate which exceeds their delivery. Synovial angiogenesis, which is mediated by factors released by 
both FLS and STM and enhances the ingress of leukocytes into the synovial tissue, is insufficient, and 
the aggressive front formed by the hyperplastic synovial lining increases the distance between blood 
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vessels and synoviocytes (32, 33). RA FLS are transformed from a quiescent state to an aggressive, 
invasive phenotype and they persist despite enrichment of apoptosis-inducing factors such as oxygen 
radicals, nitric oxide and cytokines supplied by activated STM. As such the synovium bears 
resemblance to tumor tissue and cells are likely to be subject to similarly elevated bioenergetic and 
biosynthetic demands to those seen in cancer. This comparison is summarized in Figure 1.  
It is likely that adaptation of mitochondria and cytoplasmic metabolic pathways is needed to meet the 
requirements of chronic inflammation in RA. Indeed, of the few studies which profile the metabolome 
of FLS, profound metabolic differences were identified in end stage RA when compared with OA and 
many of these are described below (34, 35). Our unpublished data shows a correlation between 
systemic inflammation (measured as CRP) and the metabolic profile of FLS from very early RA. 
However, studies comparing to healthy FLS or assessing changes during the transformation in early 
disease are lacking. Consequently, we are currently unable to determine if metabolic adaptation of 
fibroblasts is a normal response to chronic inflammation, or if primary changes to cellular metabolism 
might themselves underlie or contribute to the disease pathogenesis. Studies of STM are also few and 
most of what is known about RA macrophage metabolism is from animal models or study of cells 
differentiated in vitro from SF or peripheral blood monocytes (36). Since macrophages in healthy 
synovium are thought to be largely yolk sac-derived and cues leading to monocyte differentiation in 
tissue are poorly defined, there is a pressing need for better characterization of synovial macrophage 
subsets and their metabolism (37).      
 
The dynamic metabolic response in health 
The function of the metabolic machinery within a cell is to provide the energy and biomolecules 
necessary to perform resting and activated functions, while managing the production of potentially 
damaging byproducts such as lactate and reactive oxygen species (ROS). Recent studies of immune 
cells have identified important roles for metabolism in supporting and even directing cell 
differentiation and fate. These studies have characterized the extent of metabolic plasticity required 
for cellular responses to stimulation (8). There are 6 main pathways which are involved in these 
functions (summarized in Figure 2). Of these, oxidative phosphorylation (comprising the tricarboxylic 
acid TCA cycle and the mitochondrial electron transport chain) and fatty acid oxidation are oxygen 
dependent and take place in the mitochondria, while utilizing substrates taken up from the cytoplasm. 
Glycolysis, the pentose phosphate pathway (PPP), amino acid metabolism and fatty acid synthesis are 
oxygen independent and largely take place in the cytoplasm. However, fatty acid and amino acid 
intermediates are also shared with mitochondrial processes and use of the PPP to maintain redox 
balance does require oxygen (8).  
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Normal physiological metabolism and metabolic responses to inflammatory events are poorly studied 
in tissue resident populations such as fibroblasts and embryonically seeded macrophages(25). This is 
largely due to the practicalities of disentwining cells from the extracellular matrix, a challenge which 
researchers are making great efforts to address (38). Indeed there has been limited progress since the 
stromal metabolism field was thoroughly reviewed in 2014 (39). One study defines what is known 
about resting, healthy fibroblast metabolism, showing that fore-skin derived cells are predominantly 
glycolytic and dependent upon the PPP even in quiescence (40). This supports the anabolic processes 
associated with extracellular matrix production and is likely to also apply to FLS which maintain SF 
and produce it in excess in RA.  
Reversible regulation in the balance of cytoplasmic and mitochondrial metabolism is crucial for all 
cells to respond and adapt to changing microenvironments. Metabolic change is orchestrated by 
signaling pathways responding to nutrient, energy and oxygen levels as well as growth factor, pattern 
recognition, and cytokine receptors. The pathways involved have been reviewed elsewhere (41, 42) 
and are summarized in figure 2. These include the master regulators mechanistic target of rapamycin 
(mTOR) and 5’ adenosine monophosphate activated protein kinase (AMPK) pathways which work in 
opposition to one another. The mTOR network is a nutrient sensing system. mTORC1 or mTORC2 
complex formation downstream of PI3K or MAPK pathways induces activation of AKT and 
transcription factors HIF1α and MYC, which in turn activate glycolytic pathway genes upregulating 
aerobic glycolysis. Sterol regulatory element binding proteins (SREBP) and peroxisome proliferator-
activated receptor gamma (PPARγ) acting downstream of mTORC1 also activate genes which 
upregulate fatty acid synthesis. Other pathways have also been shown to activate glycolysis in a 
HIF1α independent manner, including the NF-κB pathway involving ubiquitous phosphofructokinase 
2 (uPFK2). AMPK is an energy sensing system often considered a metabolic checkpoint as it can 
inhibit glycolysis, control cell proliferation and promote mitochondrial biogenesis when activated 
under energetic stress (43, 44).  Downstream nuclear respiratory factor-1 (NRF-1), NRF-2 and PPARγ 
coactivator-1α (PGC-1α), as well as SIRT1 or STAT6 activated PGC-1β, induce mitochondrial 
biogenesis and fusion (discussed below), induce protective antioxidant enzymes, and promote 
oxidative metabolism. The mTOR pathway has also been shown to be important in polarization of 
macrophages to pro-inflammatory (M1) or pro-resolving (M2) phenotypes and in activation of both 
macrophage subtypes, and this has been thoroughly reviewed (45). AMPK activation in macrophages 
is associated with suppression of IL-6 production, anti-inflammatory M2 macrophage differentiation 
from SF monocytes and suppressed inflammation in K/BxN serum induced arthritis (46, 47). The 
signaling pathways which instruct stromal cell behavior are less well defined. mTOR activation has 
been linked to invasive properties in arthritic rat FLS (48). Furthermore, mice deficient in NRF2 
which acts downstream of AMPK, show more severe cartilage injuries and more oxidative damage in 
a murine model of arthritis (49). However, no link between metabolism and cell signaling has yet 
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been made in human FLS or STM and it is unknown whether signaling pathways controlling 
metabolic phenotype are dysregulated in RA.  
 
Mitochondrial responses in the RA synovium 
Under normoxic conditions mitochondrial oxidative phosphorylation is the most efficient source of 
ATP (50). In addition, mitochondria integrate various metabolic pathways and through this process 
produce intermediates needed for the synthesis of lipids, steroid hormones, and heme. Other more 
specialized mitochondrial functions include maintenance of Ca2+ homeostasis, regulation of apoptosis, 
and production of the physiological levels of ROS which act as signaling molecules (50). Importantly, 
mitochondria have mechanisms to respond spatially and temporally to heterogeneous nutrient and 
oxygen concentrations, increased ATP demands and increased stress signals including oxidative 
stress, for continued support of cellular functions and survival. These mechanisms include the 
overexpression of antioxidant enzymes and remodeling of respiratory complex subunits, changes in 
substrate choice (utilizing glutamine, pyruvate, fatty acids and ketone bodies) or switching toward 
increased glycolysis when energetic demand outpaces oxygen delivery (50).  
Changes in mitochondrial biogenesis, mitochondrial-selective autophagy (mitophagy) and in the 
equilibrium between mitochondrial fusion and fission are also critical to maintain normal 
mitochondrial and cellular function (Table 1 and Figure 3). Mitochondrial biogenesis is induced 
through the signaling pathways described above, not only in association with cell division but also in 
response to oxidative stimuli and increased energy requirements. The flux between fusion and fission 
of mitochondria in response to stress is also crucial to maintaining the metabolic capacity of the 
mitochondria as well as protecting genetic stability. Mitophagy plays a pivotal role in the maintenance 
of mitochondrial homeostasis, regulating the size and quality of the mitochondrial population. In 
addition, mitophagy eliminates damaged mitochondria under diverse stress conditions, which is 
critical as mitochondrial DNA (mtDNA) is a damage-associated molecular pattern (DAMP) that 
contributes to systemic inflammatory responses (51). Excess or inadequacy in mitochondrial 
dynamics, biogenesis and mitophagy are deleterious in mice and are associated with aging and 
multiple serious human diseases, highlighting their importance in cell phenotype and function (51, 
52). Furthermore, mitochondrial surveillance and quality control mechanisms including mitochondrial 
biogenesis and mitophagy decline with age causing progressive deterioration of mitochondrial 
function. This may have a role in diseases such as RA and suggests that targeting mitochondrial 
processes could be beneficial to restore cell function (53). 
Surprisingly little is known about mitochondrial dynamics and function in RA synoviocytes and there 
is a particular absence of observations in STM. However, a growing literature describes mitochondrial 
metabolism downstream of glycolytic glucose consumption and its role in differentiation and 
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activation of pro-inflammatory and pro-resolving monocyte-derived macrophages subtypes. These 
model systems might inform research in the synovium. For example, stimulation of macrophages with 
lipopolysaccharide (LPS) and interferon gamma (IFNγ) (so-called M1-polarising conditions) produces 
proinflammatory cells which may resemble those which populate the RA synovium. This leads to 
inhibition of the TCA cycle and the mitochondrial oxidative phosphorylation pathway to which it is 
coupled and results in upregulation of glucose transporter 1 (Glut1) to facilitate efficient uptake of 
glucose. Glucose is consumed through upregulation of aerobic glycolysis and gives rise to production 
of copious lactate which must be extruded from the cell to prevent lactic acidosis (54) . Production of 
reactive oxygen is increased, partly as a consequence of reversed electron transport by mitochondria 
and certain intermediates of the TCA cycle accumulate, notably succinate. This promotes expression 
of the pro-inflammatory cytokine IL-1β by inhibiting prolyl hydroxylases and activating the 
transcription factor HIF-1a. Succinate has also been linked to changes in methylation of DNA and 
associated histone proteins to alter gene expression (55). Furthermore, isocitrate is diverted from the 
Krebs cycle and metabolised to itaconic acid, another more recently identified TCA cycle inhibitor 
(56). RA synovial macrophages express HIF-1a, consistent with a switch to glycolytic metabolism but 
efforts are required to characterize mitochondrial metabolism and dynamics in resident and infiltrating 
STM (57). 
Several studies have observed mitochondria in late stage RA FLS. Baseline reductions in respiration 
and membrane potential (58) and changes to mitochondrial morphology (59) have been shown when 
compared with OA. Further changes suggestive of mitochondrial dysfunction such as perinuclear 
clustering of mitochondria, abnormally dark cristae, and autophagosome formation have been 
associated with lower basal mitochondrial membrane potential, as well as lower basal, maximum and 
ATP-linked mitochondrial respiratory rates (58). In a complementary study also in comparison with 
OA, we recently showed RA FLS had a higher baseline glycolytic rate to respiratory rate ratio, 
implying a shift toward reliance on glycolysis to meet the energy demand of the cells (60). Changes in 
mitochondrial metabolism can be induced in FLS by cytokines and growth factors including IL-17, 
TNF and PDGF which are associated with RA and related inflammatory conditions (58, 61). The 
reported consequences, though incompletely understood, include reduced ATP production by 
oxidative phosphorylation, production of excessive reactive oxygen and nitrogen species, 
dysregulation of Ca2+, opening of the permeability transition pore and initiation of cell death in vitro. 
Significant increases in mtDNA mutation frequency have been demonstrated in inflamed synovial 
tissue and were positively correlated with macroscopic synovitis, vascularity and SF levels of TNF 
and IFNγ (62). A further study showed that exposure of RA synovial tissue to 1% oxygen in vivo 
induced mtDNA mutations suggesting that the inflamed and hypoxic joint microenvironment may be 
eliciting the mitochondrial changes observed in RA FLS and likely to be occurring in STM (31). 
Hypoxia also altered the bioenergetics of cultured FLS by promoting a switch to glycolysis while 
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attenuating mitochondrial respiration and ATP synthesis. This supported abnormal angiogenesis, 
cellular invasion and pannus formation (59). Further in vitro studies have indicated higher mtDNA 
mutations  and ROS levels in RA compared to OA FLS (63) , correlating with elevated matrix 
metalloproteinase (MMP) expression and an invasive phenotype in RA (61, 64). 
The above findings suggest that there are mitochondrial changes in late stage RA FLS which are 
maintained in in vitro culture, yet we lack understanding of which changes are a normal response to 
meet metabolic demands of inflammation, which might play a role in driving the pathology of chronic 
disease and which are the result of damage and an increasingly hypoxic environment. In fact, 
resistance to induction of programmed cell death (apoptosis) by apoptotic signals abundant in the 
inflamed joint, is a prominent characteristic of the RA synovium (65) and sustains the synovial 
hyperplasia that characterizes the rheumatoid pannus. This would suggest that mitochondrial 
responses induced by hypoxia and inflammation in synoviocytes are able to repurpose the 
mitochondrion as a biosynthetic hub similar to that of tumor cells (66) and with conserved 
mechanisms for limiting oxidative stress and supporting effector functions and proliferation (5). 
Finally, although we lack information regarding mitophagy in the synovium, it has been suggested 
that TNF significantly induces mitophagy and mitochondrial antigen presentation in mouse 
macrophages with implications for RA (67). Several reports have shown altered autophagy in RA 
FLS, which could also contribute to synovial hyperplasia. RA FLS show an increase of genes 
involved in autophagy such as beclin-1 and LC3, which inversely correlate with their apoptosis rate 
(68, 69). In addition, RA FLS under endoplasmic reticulum stress may increase autophagy while 
becoming resistant to apoptotic death (70). Further studies are needed to understand the tangled 
relationship between metabolism, apoptosis and autophagy in synoviocytes and to identify whether 
restoring normal metabolism and mitochondrial function might have therapeutic potential in RA. 
 
Glucose metabolism in the RA synovium 
Glucose and other metabolites such as glutamine, fatty acids, and ketone bodies can be metabolized 
through the mitochondrial tricarboxylic acid (TCA) cycle in metabolically active tissues, but a shift 
away from oxidative phosphorylation towards aerobic glycolysis often occurs in response to cellular 
activation and in inflamed tissues (71). This supports various biosynthetic pathways and, 
consequently, the metabolic requirements for proliferation and cytokine production. Accelerated 
glucose metabolism is a hallmark of proliferative and activated cells (72) and can be observed with 
clinical imaging. Several studies have used fluoro-2-deoxyglucose (FDG) which is taken up by 
glycolytic cells to form FDG-phosphate, and can be shown by positron emission tomography (PET) to 
accumulate in swollen joints (73). Indeed, glycolytic inhibition by BrPa administered in a serum 
transfer animal model significantly decreased arthritis severity, highlighting the importance of glucose 
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metabolism in fueling pathological processes and making it a promising target for therapeutic 
intervention in RA (60). However, as discussed in a recent review by Weyand et al comparing 
macrophages and T cells, cells can coexist in the same microenvironment and utilize metabolites 
differently(74). This highlights the need to dissect glucose utilization in different synoviocytes since 
any successful treatment will necessarily be cell type specific.  
 
Metabolic profiling of synovial tissue has revealed that FLS consistently show altered basal glucose 
metabolism in RA (34, 35, 75), and we and others have found that stimuli such as PDGF or TNF 
increase in vitro glucose metabolism by both glycolysis and mitochondrial respiration (60). 
Furthermore, the glucose channel Glut1 is upregulated in response to hypoxia and cytokines and 
correlates with phenotypic perturbations in RA FLS (59, 60). Glucose deprivation or glycolytic 
inhibitors such as 2-deoxy-D-glucose (2-DG), bromopyruvate (BrPa) (60) and 3-(3-Pyridinyl)-1-(4-
pyridinyl)-2-propen-1-one (59) have been shown to impair cytokine secretion, proliferation, migration 
and invasion in RA FLS. Although, glucose metabolism is enhanced in activated macrophages, no 
data in STM is available yet. 
 
Diversion of glucose metabolism away from glycolysis and toward the PPP is important to support 
biosynthetic role of some cells. A role for this pathway in RA was highlighted by work on T cells 
which showed impaired glycolytic flux due to elevated pentose-shunt activity and up-regulation of 
phosphofructokinase (76). In light of RA synoviocyte mitochondrial responses and elevated ROS 
production described above, increased flux of glucose through the PPP might also be expected in 
these cells to produce cytoplasmic NADPH, and drive the reducing power of ROS detoxifying 
enzyme systems in both the cytoplasm and the mitochondrial compartments. Indeed, a global increase 
of glucose metabolism (both the PPP and glycolysis) was observed in total synoviocytes (4), and 
recent metabolite profiling of FLS (77) showed both metabolites from glycolysis and PPP were 
significantly increased in RA and compared to OA, together with other metabolites that belonged to 
the amine, fatty acid, phosphate, and organic acid classes. Although this hints toward the importance 
of the PPP, its role and the importance of NADPH production and other antioxidant mechanisms such 
as the glutathione oxidation pathway have not yet been dissected in FLS and resident STM 
populations and such research might yield new opportunities for therapeutic intervention in RA.  
 
Secondary roles have emerged for glucose metabolites, metabolic enzymes and TCA cycle 
intermediates outside of metabolism. For instance, succinate stabilizes the transcription factor HIF-1α 
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in activated macrophages and also rat synovial fibroblasts promoting glycolysis (55, 78). Succinate 
and other metabolites including α-ketoglutarate, fumarate and acetyl-CoA might be expected to 
accumulate in macrophages and FLS under hypoxic conditions and are involved in eliciting important 
epigenetic changes, with unexplored potential for driving chronic inflammation (55, 78). Also, 
essential glycolytic enzymes have been reported to translocate to the nucleus or mitochondria where 
they function independently of their canonical metabolic roles in regulation of cytokines and anti-
apoptotic responses (79, 80). For example, PKM2 also stabilizes HIF-1α promoting inflammatory M1 
macrophage differentiation. Use of a small molecule modulator of PKM2 to prevent nuclear 
translocation has potential for driving a shift toward an M2 phenotype and restoration of tolerance in 
diseases such as RA. The hexokinase (HK) enzymes are also important regulators of metabolism. 
HK1 is known to drive cleavage and activation of pro-IL-1β in macrophages via the NLPR3 
inflammasome and the downstream activation of caspase 1 (81), though this has not been studied in 
STM. HK2 also binds to the mitochondrial membrane via its interaction with the outer membrane 
porin protein (also termed the voltage-dependent anion channel (VDAC)) and this interaction inhibits 
the release of intermembrane pro-apoptotic proteins, thereby protecting cells from apoptosis. 
Importantly, the expression of HK2 is increased in RA FLS compared to OA FLS, and might provide 
an important link between metabolism and apoptosis resistance in the RA synovium (60). 
 
Lipid metabolism in the RA synovium 
Though a complex and incomplete picture, lipids are known to be important in fueling adaptive 
immunity and in resolution of inflammation (8, 82). A few studies have described lipid changes in RA 
FLS, although this has not been studied in STM. Metabolomic profiling has shown perturbation of 
lipid metabolism in RA FLS versus OA cells (34), and recent studies have identified important roles 
for molecules which interact with lipids such as choline, an important component of membrane 
phospholipids which may be limiting in proliferating cells such as RA FLS. Choline C-11 PET 
scanning, which is already in clinical use to identify prostate cancer metastasis, showed increased 
uptake in inflammatory arthritis joints (83) and choline is present at elevated levels in RA FLS and 
synovium (34, 75). Of interest, choline like transporter (CTL)1 (high-affinity) and CTL2 (low-
affinity) are also highly expressed in RA FLS and the functional inhibition of choline transporters 
promoted apoptotic FLS cell death (84). We have also shown possible therapeutic benefit in targeting 
choline kinase (ChoKα), the enzyme that catalyzes the first step in the cytidine diphosphate-choline 
pathway and which is essential for phosphatidylcholine (PC) biosynthesis. Its inhibition suppressing 
migration and enhancing apoptosis in cultured RA FLS, and significantly decreasing experimental 
arthritis in pre-treatment protocols as well as in established disease (35). Related to PC metabolism, 
phospholipase D (PLD) enzymes specifically cleave PC producing phosphatidic acid (PA) and 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
choline. Agonist-induced PLD activation results in PA synthesis thought to be involved in a variety of 
rapid cellular responses such as cytokine secretion (85). In RA FLS and RA synovial biopsy explants, 
PLD isoform-specific inhibitors significantly reduced constitutive secretion of IL-6 and IL-8, further 
highlighting the importance of phospholipid metabolism in inflammation (86). Another study showed 
that activated inflammatory arthritis FLS from humans and animal models express significant 
quantities of autotaxin, which catalyzes the conversion of lysophosphatidylcholines (LPC) to 
lysophosphatidic acid (LPA). Notably, high levels of LPC and low PC/LPC ratios in plasma were 
shown to represent a reliable measure of inflammation (87). TNF induced autotaxin expression from 
FLS and LPA, in turn, induced an activated FLS phenotype in synergy with TNF (88, 89). 
Conditional genetic ablation of autoxin in mesenchymal cells, including FLS, resulted in disease 
attenuation in animal models of arthritis (90).  
 
Metabolic coupling of cells in the RA synovium 
The problem with many of the studies described above is that they tend to treat FLS and STM as if 
they exist in isolation. But metabolism is not a private function, and metabolites produced by one cell 
can have profound effects on the biology of another. As described above, metabolites such as 
succinate, citrate and isocitrate accumulate in inflammatory macrophages and control metabolism in a 
feedback loop. It is possible that such metabolites derived from STM might have a role in influencing 
metabolism and function of proximal FLS, but this is yet to be investigated. Indeed, metabolite 
exchange between stromal and parenchymal cells is an essential function common to numerous 
metabolically active tissues including muscle, nerve, kidney, liver and testicle. SLC including the 
monocarboxylate transporters (MCT) are employed as a means of physiological metabolic coupling 
between different cell types, as extensively reviewed (91). Here macrophage-like cells commonly 
provide high-energy metabolic intermediates such as lactate and pyruvate to bioenergetically 
demanding partner cells where they can anaplerotically fuel the TCA cycle. A similar mechanism has 
been identified in epithelial cancers where both Warburg and so called ‘Reverse-Warburg’ 
metabolisms have been demonstrated and highlighted as therapeutic targets (92). The Warburg effect 
describes upregulation of aerobic glycolysis in the tumor cell itself and in the presence of ample 
oxygen. The ‘Reverse-Warburg effect’ describes a situation in which cancer-associated fibroblasts 
(CAF) provide lactate, ketone bodies and amino acids passed through MCT to fuel tumor cell 
proliferative behavior (93), as well as local angiogenesis associated with metastasis (94). Due to 
commonalities in cell behavior and microenvironment, one could hypothesize that similar symbiotic 
relationships might exist in the synovium to fuel immune cell effector function and FLS pathogenic 
behavior (Figure 4). Fujii et al showed in 2015  that late stage RA FLS have elevated levels of MCT4 
compared to OA and that siRNA knockdown of MCT4 reduced arthritis severity in the murine 
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collagen-induced arthritis model, linking their findings to apoptosis resistance and synovial 
acidification  (95). Expulsion via MCT4 is likely to be a necessary mechanism to protect cells from 
damaging effects of lactate accumulation. However, whether the lactate can be taken up and utilized 
by other cells is unknown. It is very likely that the role of MCTs and the sharing of metabolites 
between cells will differ during the course of RA as a reflection of mitochondrial health and changes 
to the joint microenvironment. Consequently, it will be important to study metabolic coupling in 
normal tissue and in the acute phase of disease to determine whether such relationships exist and if so, 
exploit their therapeutic potential, as is showing promise in cancer (96). 
 
Expanding knowledge of fibroblast metabolism 
The study of metabolism in cultured synovial cells has been important in understanding RA biology. 
Such studies have illustrated a ‘metabolic memory’ which is epigenetically imprinted upon cells in an 
inflammatory microenvironment and is lasting in in vitro culture. Metabolomic analysis continues to 
be a useful strategy for providing a metabolic snapshot on the status of such cells and to hint toward 
pathways worthy of further study. Use of technologies such as the Seahorse analyzer to observe 
bioenergetic responses, small molecule metabolic inhibitors and animal models have also played a 
role in expanding our current understanding of the field. However, for capturing the dynamic 
processes that regulate cellular metabolism, stable isotope metabolic tracer analysis is a powerful 
technique not yet applied to synoviocytes (97). This technique provides a comprehensive biological 
overview, allowing simulation and reconstruction of metabolism, and can provide insight at the 
compartment level (e.g. mitochondria versus cytoplasm, depending upon the tracer) (98). The 
increased concentration of a metabolite can be associated to either the upregulation of the enzyme 
responsible for synthesis or the downregulation of the one consuming it and metabolic tracer analysis 
allows these processes to be deconvoluted where traditional metabolomics is less informative (99, 
100). Several heavy isotopes are available and include deuterium (2H), nitrogen (15N), oxygen (18O) 
but the most commonly used is carbon (13C). The most common isotopically labeled tracers are 13C-
glucose and 13C-glutamine as these metabolites are main energy sources in many mammalian systems 
(101). Recent development of approaches to apply tandem mass spectrometry (MS/MS) to isotope 
tracing has offered the opportunity to determine positional labeling based on mass fragmentation 
(102).  
As alluded to above, studying metabolic relationships of synoviocytes after treatment (103), and 
between FLS and STM within the RA synovium is an important future direction. Stable isotope 
analysis in concert with small molecule inhibitors will allow us to trace metabolite exchange between 
cells in culture. There is also a pressing need for conditional knock out animals to observe the 
importance of metabolite channels, transporters and enzymes in inflammatory diseases as an area of 
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great therapeutic potential. Finally, better histological markers are improving our understanding of 
FLS subsets, resident and infiltrating STM and the tissue organization of these cells. Imaging mass 
spectrometry can provide a metabolomic snapshot on a per pixel basis and may reveal spatially 
distinct metabolic signatures and important metabolic heterogeneity within the synovial environment 
(104). 
 
Metabolic pathways as therapeutic targets in rheumatoid arthritis 
The metabolic rewiring of immune cells has been viewed as a promising source of novel drug targets 
(8, 14, 105) but resetting metabolism in tissues central to RA pathogenesis offers additional 
opportunities for disease modulation and restoration of homeostasis in RA. In fact, rheumatologists 
already use the antimetabolites methotrexate (MTX) and leflunomide for the treatment of patients 
with inflammatory arthritis. Both drugs inhibit the reproduction of rapidly dividing cells such as 
lymphocytes, but have also been shown to inhibit FLS functions (106, 107). Of interest, sulfasalazine, 
which was initially developed as an anti-inflammatory drug to treat rheumatoid arthritis, was 
subsequently found to inhibit XCT, a cystine–glutamate exchange transporter (108). 
Targeted approaches to metabolic inhibition are required to inhibit aggressive behavior in 
pathological cell types and leave those which aid resolution intact. Potentiation or restoration of 
protective mechanisms such as mitochondrial fusion and biogenesis and mechanisms which promote 
resolution of inflammation may also be favorable. Indeed, small molecules such as Mdivi1 which 
potentiate mitochondrial fusion have already shown potential in animal models of sepsis and may 
have further reaching applications (109). In addition, metformin is used in clinical management of 
type II diabetes and has shown promise in mouse models of arthritis (110). Though its effects on FLS 
are unknown, it is thought to act upon immune cells both by inhibiting complex I of the mitochondrial 
electron transport chain and through effects on the signaling molecule AMPK.  Other AMPK 
activators, which will control cell proliferation and promote mitochondrial biogenesis might be 
another approach (43, 44). 
Inhibitors of the signaling molecule PI3K which regulates glycolysis upstream of mTOR are in early 
stage clinical trials for cancer and show potential in RA (111). Furthermore, blockers of key 
glycolytic enzymes including phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) are 
showing promise to work in synergy with other inhibitors that target the angiogenic factor VEGF 
(112). Inhibiting glycolytic intermediates including succinate or lactate production could be of interest 
if proven to fuel synovial cell activation.  Use of a small molecule modulator of PKM2 to prevent 
nuclear translocation has also potential for driving a shift toward an M2 phenotype and restoration of 
tolerance in diseases such as RA. In FLS, HK2 release from the mitochondrial membrane could 
potentially trigger FLS apoptosis. However, a better understanding of the signaling pathways which 
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dictate the metabolic phenotype of immune and stromal cells in RA is required to capitalize on this 
area.  
Blockers of the MCT which are central to metabolic coupling have been used in as yet unpublished 
first-in-man trials for epithelial cancers, and the effects of their knockdown in experimental arthritis 
suggest they offer potential in RA (95). Other solute carrier transporters, including Glut1, aminoacids 
or choline are potential therapeutic targets yet to be explored in arthritis. Furthermore, better 
stratification of patients through prognostic metabolomic analysis (16) and techniques such as choline 
C-11 PET scanning (83) may improve treatment of non-responders to existing therapies. Overall, 
whether targeting metabolism truly presents an option to increase the drug armamentarium in 
rheumatic diseases remains to be determined. 
 
Summary 
Systemic metabolism, immunometabolism and stromal metabolism are altered in RA and a growing 
body of publications in this field offers novel biomarkers for patient stratification and avenues for 
treatment. However, we are far from an exhaustive understanding of the pathways which discern the 
normal or pathogenic phenotypes of cells resident to the synovium in order to capitalize on these 
therapeutic opportunities. It will be important to better understand mitochondrial metabolism and 
dynamics, which are sparsely studied in the synovium, with a view to harnessing fusion and 
biogenesis pathways to restore mitochondrial health and tip the balance away from aerobic glycolysis 
in RA. Future directions toward single cell transcriptomic analysis and use of cells sorted directly 
from synovial tissue promises to improve our understanding of FLS and STM biology and there is a 
need for metabolic profiling of these cells prior to dedifferentiation associated with cell culture. 
Growing evidence suggests that multiple fibroblast and macrophage subsets are present in the 
inflamed synovium and their characterization will aid in directing new treatment toward those with a 
pathogenic and not a protective phenotype. Furthermore, the metabolic interactions between FLS, 
STM and infiltrating immune cells are unexplored and lessons from cancer biology suggest this will 
provide further avenues for therapeutic intervention. There is a pressing need for techniques such as 
stable isotope-based metabolic tracer analysis to track these interactions. Finally, a strategic window 
of opportunity exists such that RA patients receiving disease modifying treatments within 3 months of 
symptom development show a much improved prognosis when compared to those treated after this 
time point (113). To date, all studies of FLS metabolism have been conducted in cells derived from 
the joints of late stage disease patients after arthroplasty and studies of macrophages have utilized 
cells differentiated from monocytes in vitro. As we begin to understand that transient metabolic 
responses in acute inflammation may differ significantly from metabolic adaptation to damage in 
chronic inflammation, characterization of cells from uninflamed and earliest stages of human disease 
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is needed to inform appropriate future therapeutic strategies with the ultimate goal of drug-free 
remission or cure for RA.  
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FIGURE LEGENDS 
Figure 1 – Similarities between the rheumatoid arthritis synovium and the solid tumor 
microenvironment. In both tissues, fibroblasts and macrophages (MØ) reside in close proximity and 
within an oxygen and nutrient deprived, cytokine rich environment. Here they sustain mitochondrial 
damage and take on a chronically activated phenotype supported by increased glycolytic metabolism. 
In RA, the fibroblasts themselves are proliferative, invasive and migratory while in cancer fibroblasts 
support proliferation, invasion and metastasis of tumor cells. Adaptive immune cell-fibroblast 
interactions differ in tumor and RA microenvironments. Activated T (green) and B (blue) cells are 
present in the synovium in RA but are suppressed in the tumor microenvironment. Little is known 
about fibroblast or macrophage metabolism in early RA and the metabolic changes which take place 
during the transition from health to disease. (ROS, reactive oxygen species). 
 
Figure 2 – Major pathways important in synoviocyte metabolism. FLS and monocyte derived 
macrophages are heavily reliant upon glucose metabolism and regulate glucose transporter member 1 
(Glut1) in response to inflammatory and stress stimuli. This fuels adenosine triphosphate (ATP) 
production in conditions of high energetic demand. Glucose is utilized in the pentose phosphate 
pathway to synthesize building blocks for nucleic acids, and to generate NADPH to control redox 
status and support lipid synthesis. Alternatively glucose is metabolized via glycolysis to pyruvate 
which is either transported into the mitochondria to contribute to tricarboxylic acid (TCA) cycle flux 
or is converted to lactate in the cytoplasm and removed from the cell via monocarboxylate transporter 
4 (MCT4). TCA cycle flux contributes to ATP production via oxidative and substrate level 
phosphorylation. When matrix citrate levels rise, citrate is transported to the cytoplasm and yields 
acetyl-CoA, the starting material for synthesis of fatty acids, cholesterol and lipids. Some such lipids 
are exported from the cell as bioactive metabolites such as sphingosine 1 phosphate (S1P), free fatty 
acids (FFA), phospholipids and eicosanoids. Acetyl-CoA as well as succinate generated from the 
TCA cycle can be utilized in production chromatin modifying enzymes (CME) and cofactors. Choline 
is taken up via choline transporter-like (CTL) 1/2 is an important substrate in FLS biology. Choline 
can be converted to betaine which is used in production CME and cofactors or converted to glycine 
for use in protein synthesis. Alternatively, choline is phosphorylated to phosphocholine and utilized in 
membrane phospholipid and bioactive lipid synthesis. A number of signalling molecules have been 
identified which control the described metabolic pathways but have sparsely been explored in FLS. 
AKT, protein kinase B; AMPK, 5’ adenosine monophosphate-activated protein kinase; G6P, glucose-
6-phosphate; HIF-1, hypoxia-inducible factor 1; Myc, Myc proto-oncogene protein; p53, cellular 
tumor antigen p53; PI3K, phosphatidylinositol 4,5-bisphosphate 3-kinase; R5P, ribose-5-phosphate; 
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S1P, sphingosine-1-phosphate; SREBP, sterol regulatory element-binding protein; mTOR, 
mechanistic target of rapamycin; PPAR, peroxisome proliferator-activated receptor gamma; NF-κB, 
nuclear factor κB pathway; uPFK, 2phosphofructokinase 2. 
 
Figure 3 – Mitochondrial dynamics; the cycle of fusion and fission. Mitochondrial morphology 
changes dynamically in response to stress and changing energetic demand. This is under the control of 
signalling molecules including sirtuin 1 (SIRT1), signal transducer and activator of transcription 6 
(STAT6), nuclear respiratory factors 1 and 2 (NRF1/2) and peroxisome proliferator-activated receptor 
gamma coactivators 1 and  (PGC-1/). Mitochondria fuse to make tubular networks under the 
control of mitofusins (MFN) 1 and 2 and optic atrophy (OPA1), a mechanism which is thought to 
increase ATP production by oxidative phosphorylation, protect mitochondrial DNA from damage in 
the presence of elevated reactive oxygen species (ROS) and leads to mitochondrial biogenesis and 
increased mitochondrial mass. Mitochondrial fission occurs under the control of dynamin related 
protein 1 (DRP1) and mitochondrial fission 1 (FIS1) and produces increased numbers of punctate 
mitochondria. Fission usually corresponds with reduced oxidative phosphorylation and increased 
aerobic glycolysis and can predispose to mitochondrial-selective autophagy (mitophagy) to regulate 
mitochondrial mass or remove damaged organelles. The box shows a number of mitochondrial 
observations made in FLS cultured from RA patients both in a resting state and after stimulation with 
proinflammatory cytokines, alluding to possible but as yet uninvestigated changes in mitochondrial 
dynamics. 
 
Figure 4 – The ‘reverse Warburg’ effect in cancer and rheumatoid arthritis? In epithelial 
tumours, the reactive oxygen species (ROS) produced by metabolically active cancer cells causes 
mitochondria-selective autophagy (mitophagy) and activate hypoxia inducible factor 1α (HIF1α) in 
local cancer-associated fibroblasts (CAF). As a result the CAF upregulate aerobic glycolysis, 
producing copious lactate which is expelled from the cell via monocarboxylate transporter 4 (MCT4) 
and taken up by the cancer cell via MCT1. Lactate, pyruvate and other metabolic intermediates such 
as amino acids and ketone bodies can feed the mitochondrial TCA cycle in cancer cells or indeed 
local endothelium to increase ATP and biomolecule synthesis and drive pathogenic proliferation, 
invasion and metastasis. MCT 1 and 4 can be blocked in vitro using the small molecule inhibitor α-
cyano-4-hydroxycinnamic acid (4CIN) and in vivo using  AZD3965, which is in early phase clinical 
trials for treatment of small cell lung cancer. In RA it is known that mitochondrial damage, HIF1α 
activation and upregulation of MCT4 can be induced in late stage disease FLS by the pathogenic 
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microenvironment but the metabolic relationships between these cells and other cells within the joint 
have yet to be elucidated. 
 
Term Definition in the context of this review 
Aerobic glycolysis 
 
The metabolic pathway which utilizes glucose to generate ATP in the presence 
of oxygen. End products of this process are pyruvate which can be imported into 
mitochondria for use in the TCA cycle or lactate which is expelled from the cell 
as waste. 
Anabolism The enzymatic synthesis of molecules from smaller components.  
Anaplerosis  The replenishment of metabolic intermediates into the TCA cycle as substrates 
for biosynthesis and the generation of ATP. 
Bioenergetics The study of energy production by cells. Often associated with use of the 
Seahorse analyzer to assess glycolysis and oxidative phosphorylation rates in 
real time. 
Catabolism The enzymatic degradation of molecules into smaller products. 
Cataplerosis The removal of TCA cycle intermediates for use in biosynthesis or to prevent 
build up within mitochondria. 
Electron transport chain 
 
A set of complexes of the inner mitochondrial membrane that shuttle electrons 
from NADH and FADH2 to oxygen. The redox reactions of the chain produce an 
electrochemical gradient of protons across the membrane which drives synthesis 
of ATP by oxidative phosphorylation. 
Hypoxia Oxygen deficiency in tissues, such that oxygen tension is below that of healthy 
physiological conditions. Normal oxygen levels differ between tissues and 
therefore the level at which a tissue is considered to be hypoxic is variable. The 
RA joint has an oxygen tension of 8% in health and <3% in RA. 
Imaging mass spectrometry  A mass spectrometry based technique which allows the spatial distribution of the 
metabolome to be visualized in a tissue section. This offers insights into where 
pathogenic metabolic changes are taking place in tissues and is yet to be applied 
to the synovium.   
Immunometabolism The research field which investigates metabolism in the context of immunity and 
inflammation. As stromal cells are crucial to both induction and resolution of 
these processes, we consider the study of their metabolic processes to be 
embedded in this field. 
Metabolic coupling The transfer of metabolites between cells in a manner which benefits the 
biosynthetic and bioenergetic requirements of the recipient cell. 
Metabolic flux analysis   
 
Also known as ‘stable isotope metabolic tracer analysis’, this is a 13C isotope 
tracing methodology involving incubation of cells with a stable isotope, 
quantitation of metabolite labeling using mass spectrometry or NMR 
spectroscopy, and computational fitting of the data to a model allowing estimates 
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of pathway-specific flux.  
Metabolic memory 
 
Imprinting of a metabolic phenotype on a cell by cues within its 
microenvironment, such that the phenotype is maintained after the cues are 
removed or the cells is removed from the tissue.  
Metabolome All substrates, intermediates and products of metabolism associated with a given 
system or compartment. These may be intracellular or extracellular.  
Metabolomics  Used synonymously with the term ‘metabolic profiling’, this is the identification 
and measurement of all or a targeted set of metabolites within a body fluid, cell 
population or tissue conducted by NMR spectroscopy or mass spectrometry. 
Mitochondrial biogenesis  The generation of greater mitochondrial mass to increase  the capacity for 
mitochondrial function and ATP production within a cell; this process is 
important to health but is uninvestigated in RA.  
Mitochondrial dynamics  The balance and transition between mitochondrial fusion and fission, movement 
and degradation; processes which are important to health but in uninvestigated in 
RA. 
Mitochondrial fission  The division of mitochondrial networks into individual, punctate organelles, 
principally controlled by outer membrane proteins DRP1 and FIS1. 
Mitochondrial fusion  The formation of tubular mitochondrial networks through MFN1, MFN2 and 
OPA1 mediated joining of individual organelle membranes. This process is 
associated with increased ATP production and protection of mitochondrial DNA 
from reactive oxygen species.  
Mitophagy ‘Mitochondrial-selective autophagy’. The selective degradation of defective 
mitochondria without the release of inflammatory mitochondria- associated 
DAMPS.  
Oxidative phosphorylation  Generation of ATP by the mitochondrial ATP synthase and driven by the 
electrochemical gradient of protons generated by the electron transport chain. 
Pentose phosphate pathway 
 
The pathway which oxidizes glucose to generate NADPH for the maintenance of 
the cellular redox balance and 5 carbon sugars utilized in anabolic processes 
such as nucleic acid synthesis.  
Positron emission tomography 
 
Use of a radioactive tracer isotope incorporated into a metabolic substrate to 
visualize  metabolizing cells in a whole organism. Commonly, labelled glucose 
is used to identify tumors but is also useful in highlighting sites of inflammation 
such as the RA joint. 
Reverse Warburg effect –  
 
The production of high energy metabolic intermediates by one cell to 
anaplerotically feed ATP production by a neighboring cell. Currently 
characterized only in epithelial tumors where cancer-associated fibroblast feed 
lactate and other metabolites to tumor cells through channels such as the 
monocarboxylate transporters. 
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TCA cycle 
 
The tricarboxylic acid cycle is a series of chemical reactions which take place in 
the mitochondrial matrix generating ATP by substrate level phosphorylation and 
NADH and FADH2 by oxidation of fuel molecules.  The NADH and FADH2 are 
further oxidized by the electron transport chain.   
Warburg effect  Pathological increase in glycolysis associated with reduced oxidative 
phosphorylation despite the presence of oxygen. This describes a cellular 
bioenergetic phenotype classically associated with tumor cells but now also 
associated with activated immune cells. 
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